Soleno Therapeutics (SLNO) Income from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has 3 years of Income from Discontinued Operations data on file, last reported at 130000.0 in Q4 2018.

• On a quarterly basis, Income from Discontinued Operations rose 76.7% year-over-year to 130000.0 in Q4 2018; TTM through Dec 2018 was 2201000.0, a 42.21% increase from a year earlier, with the FY2018 full-year figure at 1494000.0, up 56.05% from the prior year.
• Income from Discontinued Operations for Q4 2018 stood at 130000.0, up from 427000.0 in the prior quarter.
• Over the last five years, Income from Discontinued Operations for SLNO reached as high as 130000.0 in Q4 2018 and fell as low as 1191594.0 in Q4 2016.
• Historically, Income from Discontinued Operations has averaged 727599.0 across 3 years, with a median of 765500.0 in 2016.
• Across the five-year window, Income from Discontinued Operations dropped 11.61% in 2017 and jumped 76.7% in 2018, its largest moves.
• Year by year, Income from Discontinued Operations stood at 1191594.0 in 2016, then surged by 53.17% to 558000.0 in 2017, then soared by 76.7% to 130000.0 in 2018.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were 130000.0 in Q4 2018, 427000.0 in Q3 2018, and 558000.0 in Q4 2017.